Yong-sheng Tu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
In multiple myeloma, despite recent improvements offered by new therapies, disease relapse and drug resistance still occur in the majority of patients. Therefore, there is an urgent need for new drugs that can overcome drug resistance and prolong patient survival after failure of standard therapies. The imipridone ONC201 causes downstream inactivation of(More)
  • 1